Moderna Ramps Down mRNA Drug Substance Production For Its Covid-19 Vaccine At Lonza; Will Ramp Down Production Of mRNA Drug Substance For Its Covid-19 Vaccine At Lonza's Site In Visp, Switzerland, In Q3 2023
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced plans to reduce production of mRNA drug substance for its Covid-19 vaccine at Lonza's site in Visp, Switzerland, in Q3 2023.
September 19, 2023 | 2:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The reduction in Moderna's production at Lonza's Swiss site could have a minor impact on Switzerland's economy, potentially affecting the EWL ETF.
Moderna's decision to reduce production at Lonza's site in Switzerland could have a minor impact on the Swiss economy. This could potentially affect the performance of the EWL ETF, which tracks the investment results of an index composed of Swiss equities.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
Moderna's decision to reduce mRNA drug substance production could potentially impact its vaccine supply and revenue.
Moderna's decision to reduce production of mRNA drug substance at Lonza's site could potentially lead to a decrease in the supply of its Covid-19 vaccine. This could impact the company's revenue and profitability, leading to a potential decrease in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100